Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Low-dose interferon-alpha preconditioning and adoptive cell therapy in patients with metastatic melanoma refractory to standard (immune) therapies: a phase I/II study.
Verdegaal E, van der Kooij MK, Visser M, van der Minne C, de Bruin L, Meij P, Terwisscha van Scheltinga A, Welters MJ, Santegoets S, de Miranda N, Roozen I, Liefers GJ, Kapiteijn E, van der Burg SH. Verdegaal E, et al. Among authors: de bruin l, de miranda n. J Immunother Cancer. 2020 Mar;8(1):e000166. doi: 10.1136/jitc-2019-000166. J Immunother Cancer. 2020. PMID: 32238469 Free PMC article. Clinical Trial.
Phase I/II study protocol to assess safety and efficacy of adoptive cell therapy with anti-PD-1 plus low-dose pegylated-interferon-alpha in patients with metastatic melanoma refractory to standard of care treatments: the ACTME trial.
van der Kooij MK, Verdegaal EME, Visser M, de Bruin L, van der Minne CE, Meij PM, Roozen ICFM, Jonker MA, van den Bosch S, Liefers GJ, Speetjens FM, van der Burg SH, Kapiteijn E. van der Kooij MK, et al. Among authors: de bruin l. BMJ Open. 2020 Nov 24;10(11):e044036. doi: 10.1136/bmjopen-2020-044036. BMJ Open. 2020. PMID: 33234662 Free PMC article.
Enhanced antigen cross-presentation in human colorectal cancer-associated fibroblasts through upregulation of the lysosomal protease cathepsin S.
Harryvan TJ, Visser M, de Bruin L, Plug L, Griffioen L, Mulder A, van Veelen PA, van der Heden van Noort GJ, Jongsma ML, Meeuwsen MH, Wiertz EJ, Santegoets SJ, Hardwick JC, Van Hall T, Neefjes J, Van der Burg SH, Hawinkels LJ, Verdegaal EM. Harryvan TJ, et al. Among authors: de bruin l. J Immunother Cancer. 2022 Mar;10(3):e003591. doi: 10.1136/jitc-2021-003591. J Immunother Cancer. 2022. PMID: 35264435 Free PMC article.
Neoantigen Targetability in Progressive Advanced Melanoma.
van den Bulk J, Verdegaal EME, van der Ploeg M, Visser M, Nunes JB, de Ru AH, Tjokrodirijo RTN, Ijsselsteijn ME, Janssen NI, van der Breggen R, de Bruin L, de Kok P, Janssen GMC, Ruano D, Kapiteijn EHW, van Veelen PA, de Miranda NFCC, van der Burg SH. van den Bulk J, et al. Among authors: de bruin l. Clin Cancer Res. 2023 Oct 13;29(20):4278-4288. doi: 10.1158/1078-0432.CCR-23-1106. Clin Cancer Res. 2023. PMID: 37540567 Free PMC article.
Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer.
Verdegaal EME, Santegoets SJ, Welters MJP, de Bruin L, Visser M, van der Minne CE, de Kok PM, Loof NM, Boekestijn S, Roozen I, Westra IM, Meij P, Van der Burg SH, Kroep JR. Verdegaal EME, et al. Among authors: de bruin l. J Immunother Cancer. 2023 Nov;11(11):e007697. doi: 10.1136/jitc-2023-007697. J Immunother Cancer. 2023. PMID: 37949617 Free PMC article.
Perioperative hospital mortality at a tertiary paediatric institution.
de Bruin L, Pasma W, van der Werff DB, Schouten TA, Haas F, van der Zee DC, van Wolfswinkel L, de Graaff JC. de Bruin L, et al. Among authors: de graaff jc. Br J Anaesth. 2015 Oct;115(4):608-15. doi: 10.1093/bja/aev286. Br J Anaesth. 2015. PMID: 26385669 Free article.
Legionella longbeachae; don't miss it!
de Bruin L, Timmerman CP, Huisman PM, Heidt J. de Bruin L, et al. Neth J Med. 2018 Aug;76(6):294-297. Neth J Med. 2018. PMID: 30152395 Free article. Review.
European Joint Programme on Rare Diseases workshop: LAMA2-muscular dystrophy: paving the road to therapy March 17-19, 2023, Barcelona, Spain.
Smeets H, Verbrugge B, Bulbena X, Hristova L, Vogt J, van Beckhoven I; all participants; Patient organizations/patient representatives: LAMA2-Europe, Voor Sara-the Netherlands, ImpulsaT-Spain, LAMA2-France, CMD-Turkey, LAMA2-Bulgaria, Cure-CMD. Smeets H, et al. Neuromuscul Disord. 2024 Mar;36:16-22. doi: 10.1016/j.nmd.2024.01.001. Epub 2024 Jan 9. Neuromuscul Disord. 2024. PMID: 38306718
57 results